AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06643832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubbing Distraction
Description: gently touching on proximal part of the IV injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.
Study NCT06643832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: lidocaine will be used by mixing it with the propofol before intravenous injection
Study NCT06643832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous propofol will be given without mixing with any drug (except for 2 ml saline to ensure blindness of the outcome assessor).
Study NCT06443125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural psychotherapy
Description: Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
Study NCT04932434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Description: * Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring
Study NCT06098755 — intervention group
Intervention type: BEHAVIORAL
Intervention: Transcendence Research: Holistic Education
Description: With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
Study NCT06228079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy,Toripalimab Injection
Description: Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
Study NCT06228079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy,Gemcitabine based regimen
Description: Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
Study NCT05700448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Description: IV infusion
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegaspargase
Description: Intramuscular injection
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Intramuscular injection
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion
Study NCT05700448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion
Study NCT05453773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05453773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Smoking
Description: Smoke waterpipe tobacco
Study NCT05193149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Training of respiratory muscles
Study NCT06307964 — intervention group
Intervention type: PROCEDURE
Intervention: Biological sampling
Description: * A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible
Study NCT05193149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Supervised aerobic exercise intervention
Study NCT05193149 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise training
Description: Supervised aerobic exercise intervention
Study NCT05508737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
Description: arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
Study NCT04461301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
Study NCT06316856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
Study NCT06316856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
Study NCT06316856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Newly matched donor-derived CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
Study NCT05136417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-procedural intracardiac echocardiography (ICE) probe
Description: placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
Study NCT05989308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email
Description: Email message sent to guardian with proxy information.
Study NCT05989308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Text message sent to guardian with proxy information.
Study NCT05989308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Portal Message
Description: Patient portal message (MyChart) to guardian with proxy information.
Study NCT05569122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike
Study NCT05569122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pGz Bed
Description: Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
Study NCT05569122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
Study NCT05569122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise Pedal
Description: Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
Study NCT05569122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason® contrast agent
Description: Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
Study NCT05501379 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study only
Description: No intervention - observational study only
Study NCT04758637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Notification
Description: We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
Study NCT04345250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
Study NCT04298905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHW mHealth patient intervention for trigger escalation
Description: The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~1. NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~   1. Triggered, escalating adherence coaching:~  2. Safety monitoring: reports all abnormal laboratory values to provider~2. Appointment keeping (RETAIN):~   a. Triggered, escalating adherence coaching~3. vDOT submissions:~   a. Triggered, escalating adherence coaching~4. Symptom reports:~   1. Triggered, escalating adherence coaching
Study NCT05692674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant hypofractionated intensity-modulated proton radiotherapy
Description: CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
Study NCT05071053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab (CYRAMZA®)
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion
Study NCT05071053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine (SAR408701)
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion
Study NCT06309953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: Miebo treatment
Study NCT06544421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions
Study NCT05667246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeinated Coffee
Description: Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee.
Study NCT05180487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
Study NCT05384522 — intervention group
Intervention type: OTHER
Intervention: blood samples collection
Description: Blood samples will be drawn at baseline and at 6 and 12 months from baseline
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 100 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 100 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 100 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 200 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 200 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 200 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 300 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 300 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 300 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 400 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 400 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 400 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 600 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 600 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet,Single dose of Placebo 600 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 800 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 800 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 800 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 200 mg (MAD)
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 400 mg (MAD)
Description: Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 600 mg (MAD)
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
Study NCT06155487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
Study NCT06551116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CE-10-IVD
Description: Leftover tumor tissue from a routine biopsy will be sent for analysis.
Study NCT06575985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation and exercise training
Description: 10-day intervention consisting of daily 60-min exercise sessions aimed to induce increases in core body temperature, conducted in a climactic chamber set to 35°C and 50% relative humidity.
Study NCT06575985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermo-neutral exercise training group
Description: 10-day intervention consisting of daily 60-min exercise sessions conducted in a climactic chamber set to 23°C and 50% relative humidity.
Study NCT05984940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho MTA cement
Description: Ortho MTA has a fine granularity for only 2 microns. It penetrates into dental tubules and fuses itself to the surface where it is applied. In addition, it prevents micro-leakage by forming an interfacing layer of hydroxyapatite (Hap) between the OrthoMTA and the canal wall.
Study NCT05984940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP and AH Plus sealer
Description: AH Plus Sealer is a calcium silicate-based root canal sealer. Tricalcium Silicate interacts with body fluids to release calcium and hydroxide ions that promote hydroxyapatite (HA) formation.
Study NCT04917822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
Study NCT04917822 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information provision
Description: Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
Study NCT05618678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIGNITY
Description: DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
Study NCT05618678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infection Control
Description: This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
Study NCT05667246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated Coffee
Description: Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee.
Study NCT04938206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Clinical Decision Rule
Description: The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
Study NCT04938206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Clinical Decision Rule
Description: The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
Study NCT06414434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
Study NCT05758337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibropneumostimulation
Description: New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
Study NCT04890171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: Endoscopic submucosal dissection by a endoscopist using endoscopic devices